K34c

Cat. No.:	HY-150124
CAS No.:	939769-93-4
Molecular Formula:	$C_{26}H_{29}N_3O_4$
Molecular Weight:	447.53
Target:	Integrin
Pathway:	Cytoskeleton
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	K34c is a potent and selective α5β1 integrin antagonist. K34c can be used for glioblastoma research[1].
IC_{50} & Target	α5β1

In Vitro

K34c (20 μM; 24 or 48 h) significantly induces U87MG cells apoptosis in combination with 1 μM Ellipticine (HY-15753)[1].
K34c (20 μM; 48 h) decreases significantly Temozolomide (HY-17364)-induced senescence in cells transfected with control non targeting siRNA without affecting significantly the residual senescence of cells transfected with siRNA specific for p53[1].
K34c (20 μM; 24 h) modulates the p53 pathway.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis[1]

Cell Line:	U87MG cells
Concentration:	20 μM
Incubation Time:	24 or 48 h
Result:	Induced apoptosis, led to a significant increase in apoptotic cell death measured by the population of sub-G1 cells in combination with 1 μM Ellipticine (HY-15753).

Western Blot Analysis[1]

Cell Line:	U87MG cells
Concentration:	20 μM
Incubation Time:	24 h
Result:	Decreased Ellipticine (HY-15753)- and Temozolomide (HY-17364)-induced activation of p53.

REFERENCES

[1]. Martinkova E, et al. alpha5beta1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells. Int J Cancer. 2010 Sep 1;127(5):1240-8.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA